# DESCRIPTION

## STATEMENT OF GOVERNMENT INTEREST

- state government interest

## 1. BACKGROUND OF THE INVENTION

- motivate cancer treatment
- describe ATF5 role in cancer

## 2. SUMMARY OF THE INVENTION

- summarize invention

## 4. DETAILED DESCRIPTION OF THE INVENTION

- define ATF5 protein and analogues
- describe ATF5 expression in various tumor types
- introduce dominant-negative ATF5 (d/n-ATF5) peptides
- describe d/n-ATF5 peptide sequences and encoding nucleic acids
- define cell-penetrating peptides (CP) and their properties
- describe CP-d/n-ATF5 peptides and their encoding nucleic acids
- introduce alternative CP peptides (e.g., penetratin, transportan, pIsl, TAT, pVEC, MAP, MTS)
- describe CP-d/n-ATF5 peptides comprising alternative CP sequences
- summarize CP-d/n-ATF5 peptide properties and uses
- define MAPs
- describe covalent and non-covalent linkages
- outline conjugation strategy
- discuss protein synthesis and analogues
- describe use of d/n-ATF5 compositions
- define neural tumors
- classify brain tumors
- describe gliomas
- outline method of promoting apoptosis
- describe pharmaceutical compositions
- outline administration methods
- describe therapeutic compositions
- provide kits for treating tumors

## 5. EXAMPLES

### 5.1 CP-d/n-ATF5 Example

- describe materials and methods for CP-d/n-ATF5 example
- detail protein production and bioassay
- perform mass spectroscopy analysis
- conduct bioactivity and cell penetrating assays
- describe retrovirus-induced mouse glioblastoma model and treatment
- generate cell-penetrating d/n-ATF5
- design and express Pen-d/n-ATF5-RP
- test Pen-d/n-ATF5-RP in glioblastoma cells
- evaluate systemic delivery of Pen-d/n-ATF5-RP in mice
- assess long-term therapeutic efficacy of Pen-d/n-ATF5-RP
- present experimental results
- discuss implications of results
- describe additional cell lines and compositions
- demonstrate synergy with existing treatments

